The decline in India's daily Covid-19 cases has ensured a consistent fall in the active caseload, which constitutes 2.36 per cent of the total infections, health ministry has said
Daily new Covid-19 cases in the country remained below 20,000 for the third consecutive day, while higher testing has led to further decline in the cumulative positivity rate to 5.89 per cent
Prime Minister Narendra Modi on Monday said India is soon going to start the largest vaccination programme in the world
EU nations and the United States have refused Venezuela's request to unfreeze its assets, so that the sanctions-hit country could purchase a coronavirus vaccine, President Nicolas Maduro has said
The overall number of global coronavirus cases has surpassed the 85 million mark, while the deaths have surged to more than 1.84 million, according to the Johns Hopkins University
The United Kingdom registered 54,990 COVID-19 cases within the past 24 hours, a drop from 57,725 the day before, according to government figures
Trump on Sunday said that the record-breaking numbers of new Covid-19 cases, nearly 300,000 in the past 24 hours, are exaggerated due to the Centers for Disease Control (CDC) method of counting
Most vaccines are not yet available in plenty, and are costly, too
Here's a selection of Business Standard opinion pieces for the day.
Health Minister Harsh Vardhan termed it a 'watershed moment in India's battle against Covid-19'
US distributes over 13 million doses of vaccines; 4.2 million administered
First a scientist and then a businessman, founder chairman Krishna Ella quit his faculty position at the Medical University of South Carolina in Charleston, United States, in 1996 to return to India
MRP for private market Rs 1,000/ dose; current licence does not allow export or sale in private market
While the Oxford-AstraZeneca vaccine made by Serum Institute here has 70.42% efficacy, Bharat Biotech's still does not have efficacy data as trials are underway in India
It took a chance by ramping up capacity on vaccines when they were yet to be approved and is set to emerge a global winner
Bharat Biotech's Covaxin is based on a whole inactivated virus platform, an old technology which is used to make vaccines given to infants
Forecasting is a hit or miss business even in normal times. And at a time when even hindsight is not 2020, predict at your own peril what will happen in 2021
Nationwide roll-out needs meticulous planning
However, he said that many countries, especially the European Union, are likely to step up production and increase their portfolios in an attempt to reduce import reliability.
Company to initiate trials with around 30,000 volunteers